Edition:
India

Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

5.02USD
10:45pm IST
Change (% chg)

$0.36 (+7.73%)
Prev Close
$4.66
Open
$4.77
Day's High
$5.02
Day's Low
$4.75
Volume
79,881
Avg. Vol
349,341
52-wk High
$5.78
52-wk Low
$2.27

Summary

Name Age Since Current Position

Paul Meister

67 2019 Independent Chairman of the Board

Chirag Patel

53 2019 President, Co-Chief Executive Officer, Director

Chintu Patel

48 2019 Co-Chief Executive Officer, Co-Founder, Director

Anastasios Konidaris

53 2020 Chief Financial Officer, Senior Vice President

Sanjay Jain

President - India

Nikita Shah

42 2018 Chief Human Resource Officer, Senior Vice President

Andrew Boyer

54 2018 Executive Vice President - Commercial Operations

Stephen Manzano

54 Senior Vice President, General Counsel & Corporate Secretary

Joseph Greer

Senior Vice President - Global Quality Management

Apurva Saraf

Senior Vice President - Corporate Development

Joseph Todisco

Senior Vice President - Specialty Commercial

Gautam Patel

47 2018 Director

Emily Alva

45 2018 Independent Director

J. Kevin Buchi

64 2018 Independent Director

Jeffrey George

46 2019 Independent Director

John Kiely

61 2019 Independent Director

Ted Nark

61 2018 Independent Director

Shlomo Yanai

67 2019 Independent Director

Biographies

Name Description

Paul Meister

Mr. Paul M. Meister serves as Independent Chairman of the Board of the Company. Mr. Meister served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries. Mr. Meister was Chairman of Thermo Fisher Scientific, Inc., a scientific instruments equipment and supplies company, from November 2006 to April 2007. He was previously Vice Chairman of Fisher Scientific International, Inc., a predecessor of Thermo Fisher Scientific, Inc., from 2001 to 2006, and Chief Financial Officer of Fisher Scientific International, Inc. from 1991 to 2001. Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company. Mr. Meister holds a bachelor of arts degree from the University of Michigan and a master of business administration from Northwestern University. He currently serves as a director on the boards of Aptiv PLC, Quanterix Corporation, Oaktree Acquisition Corp. and Scientific Games Corporation. He previously served as a director of vTv Therapeutics and LKQ Corporation until 2018 and as a director of Revlon until 2019.

Chirag Patel

Mr. Chirag Patel serves as President, Co-Chief Executive Officer, Director of the Company. Mr. Patel serves on the board of managers of each of these companies. Mr. Patel also serves on the boards of Liberty Science Center®, the Art of Living Foundation® and the New Jersey City University Foundation, and is a recipient of the Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel’s long experience as an entrepreneur in the healthcare industry as a co-founder and leader of numerous successful pharmaceutical businesses, including Amneal, gives him deep understanding of the pharmaceutical industry and extensive expertise in the wide range of strategic, commercial, financial and operational matters relevant to Amneal.

Chintu Patel

Mr. Chintu Patel serves as Co-Chief Executive Officer, Co-Founder, Director of the Company. Mr. Chintu Patel has served as Co-Chief Executive Officer and director of the Company since August 2019. He served as a Co-Chairman of the Board from May 2018 to August 2019, and previously served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2002 until the Combination. Mr. Patel holds a bachelor’s degree in pharmacy from Rutgers College of Pharmacy. He also holds an honorary doctorate degree from Long Island University. With his brother, Chirag Patel, Mr. Patel built the Amneal Alliance including Kashiv Biosciences, LLC (“Kashiv”) (engaged in the development of pharmaceutical and biosimilar pharmaceutical products), Asana Biologics, LLC (“Asana”) (an early stage drug discovery and R&D company focusing on several therapeutic areas, including oncology, pain and inflammation) and Prolong Pharmaceuticals, LLC (“Prolong”) (an early stage biotechnology company focused on new branded hematology and oncology products). Mr. Patel serves on the board of managers of each of these companies. Mr. Patel also serves on the boards of Long Island University, the Long Island Association and the Make-a-Wish Foundation®, and is a recipient of the Ernst & Young National Entrepreneur of the Year Life Sciences Award®.

Anastasios Konidaris

Mr. Anastasios G. Konidaris serves as Chief Financial Officer, Senior Vice President of the Company. He joins the Company from Alcresta Pharmaceuticals, LLC, a specialty pharmaceutical company, where he has served as Executive Vice President and Chief Financial Officer since March 2016. Prior to joining Alcresta Pharmaceuticals, Mr. Konidaris served as Senior Vice President and Chief Financial Officer of Ikaria, Inc., a biotherapeutics company, from October 2011 to May 2015. From 2007 to May 2015, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet Corporation, a leading commercial information services company, where he also served as Principal Accounting Officer and led the Global Finance Operations from 2005 to 2007. From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company. Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company.

Sanjay Jain

Mr. Sanjay Jain serves as President - India of the Company. Sanjay has oversight for all aspects of Amneal India operations, including managing the overall productivity and quality deliverables. He has extensive experience managing Operations, Validation and Quality, as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences.

Nikita Shah

Ms. Nikita Shah serves as Chief Human Resource Officer, Senior Vice President of the Company. Nikita has served as our Senior Vice President, Chief Human Resources Officer since the Combination, and from January 2014 to the completion of the Combination, as Senior Vice President, Corporate Affairs & Human Resources of Amneal. Ms. Shah oversees human resources for the Company. Prior to joining Amneal, Ms. Shah led the internal audit and human resources functions for Warner Chilcott, a global specialty pharmaceutical company, from 2007 to 2014. She also supported corporate M&A, process improvements and systems efficiencies across the organization.

Andrew Boyer

Mr. Andrew S. Boyer serves as Executive Vice President - Commercial Operations of the Company. Prior to joining Amneal, Mr. Boyer served as President & CEO of North America Generics, Teva Pharmaceutical Industries Ltd. from August 2016 to February 2018. Before that, Mr. Boyer was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan from September 2006 to August 2016. Mr. Boyer joined Allergan (then known as Watson Pharmaceuticals) in 1998 as Associate Director of Marketing in Generics. Before joining Allergan, Mr. Boyer served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Mr. Boyer received his bachelor’s degree in Business Administration and Management from State University of New York at Albany.

Stephen Manzano

Mr. Stephen Manzano Esq. serves as Senior Vice President, General Counsel & Corporate Secretary of the Company. Steve is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in private corporate and financial transactional practice as well as leading in-house corporate legal teams in the pharmaceutical sector. Most recently, Steve concurrently served for 11 years as Group Vice President, General Counsel, Secretary & Head of Corporate Compliance for both Sun Pharmaceuticals and majority-owned subsidiary, Taro Pharmaceuticals Industries. Steve holds a Bachelor of Science degree in Public Administration & Political Science from James Madison University and a Juris Doctor degree from Tulane Law School.

Joseph Greer

Mr. Joseph (Joe) Greer serves as Senior Vice President - Global Quality Management of the Company. Joe is responsible for leading quality management globally and has more than 27 years of quality and regulatory experience in positions with G&W Labs, Perrigo, KVD Pharma, Pliva, Barr Laboratories, and Novartis Pharmaceuticals. Joe is an active member of various industry organizations, including the American Chemical Society, Regulatory Affairs Professionals Society and the American Society for Quality.

Apurva Saraf

Mr. Apurva Saraf serves as Senior Vice President - Corporate Development of the Company. Apurva leads Amneal’s Global Corporate Development function and is responsible for the company’s global strategic and business development initiatives. Apurva has been part of the extended executive leadership team since joining Amneal in 2012 and has broad experience in commercial operations across various channels and in negotiating and integrating M&A transactions globally. While at Amneal, Apurva also co-founded Gemini Laboratories, a successful specialty pharmaceuticals company. Prior to Amneal, Apurva served in positions of increasing responsibility, including head of North America business development, for Ranbaxy USA. Prior to Ranbaxy, Apurva was an equity analyst, with UBS, JPMorgan and Credit Suisse in New York, covering the Specialty and Generic Pharmaceuticals sector.

Joseph Todisco

Mr. Joseph Todisco serves as Senior Vice President - Specialty Commercial of the Company. Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the Amneal-Impax integration process. Joe joined Amneal six years ago as the head of Corporate Development and has been an integral part of the management team that executed the Amneal-Impax business combination, as well as multiple other business development, licensing and M&A transactions. In addition to his role in Corporate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies.

Gautam Patel

Mr. Gautam Patel serves as Director of the Company. Prior to joining Tarsadia, Mr. Patel served as Managing Director at Lazard from 2008 to 2012, where he led financial and strategic advisory efforts in sectors including transportation and logistics, private equity, and healthcare. Prior to that, Mr. Patel served in a variety of advisory roles at Lazard from 1999 to 2008, including multiple restructuring, bankruptcy and corporate reorganization assignments in 2001 and 2008. From 1994 to 1997, Mr. Patel was an Analyst at Donaldson, Lufkin & Jenrette, where he worked on M&A as well as high-yield and equity financings. Mr. Patel is currently a Board Member of several private companies such as Kashiv, Asana Biosciences, Prolong Pharmaceuticals, Envisics and AIONX Antimicrobial Technologies. Mr. Patel also serves on the board of Casita Maria Center for Arts & Education, a New York based non-profit organization that aims to empower children through arts-based education. Mr. Patel received a bachelor of art degree from Claremont McKenna College, a bachelor of science degree from Harvey Mudd College, an MSc from the London School of Economics and an MBA from the University of Chicago. Mr. Patel brings an extensive knowledge of the Company’s business and operations combined with deep experience in finance, corporate development and healthcare investing to the Board.

Emily Alva

Ms. Emily Peterson Alva serves as Independent Director of the Company. Ms. Alva is a financial, strategic and business advisor to senior executives, founders and corporate boards of directors, and has focused on private company advisory projects and family office investing since 2013. Prior to that time, Ms. Alva spent more than 15 years at Lazard as a senior mergers & acquisitions investment banker advising industry leading companies. Ms. Alva’s extensive advisory and transaction work covers multiple industries with a primary sector focus and expertise in healthcare. While at Lazard, Ms. Alva held leadership roles, both with clients and internally. She advised some of Lazard’s most important clients over many years, and was one of the youngest bankers promoted to Managing Director at the firm. During her Lazard tenure, Ms. Alva was selected for the Council on Foreign Relations’ Corporate Leaders Program, which recognizes accomplished professionals on a senior management track and links business leaders with decision makers in government and academia. Prior to joining Lazard, Ms. Alva worked at a development stage company focused on engineering-based solutions to improve industrial waste processing systems. More recently, Ms. Alva has served as a Board Member and Treasurer for the Alumnae Board of Directors of Barnard College. Ms. Alva received a BA in Economics from Barnard College, Columbia University

J. Kevin Buchi

Mr. J. Kevin Buchi serves as Independent Director of the Company. Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from October 2011 to May 2012. Prior to Teva, Mr. Buchi served as CEO of Cephalon, Inc. (formerly Nasdaq: CEPH), which was subsequently acquired by Teva, from December 2010 to October 2011, and held various positions at Cephalon, including Chief Operating Officer from January 2010 to December 2010 and Chief Financial Officer from 1996 to 2009. Since April 2013, Mr. Buchi has served as a director and member of the remuneration and nominating committee, and audit committee of the board of Benitec Biopharma Ltd. (Nasdaq: BNTC), a biotechnology company headquartered in Australia. Since August 2018, Mr. Buchi has served as a director and chairman of the board of Dicerna Pharmaceuticals (Nasdaq: DRNA). Mr. Buchi previously served as a director until 2016 of the following companies: Epirus Biopharmaceuticals, Alexza Pharmaceuticals, Stemline Therapeutics, and Forward Pharmaceuticals. Mr. Buchi received his BA degree from Cornell University and a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi’s extensive experience as a senior executive and board member in the pharmaceutical industry provides the Board with unique insights into our business.

Jeffrey George

Mr. Jeffrey (Jeff) P. George serves as Independent Director of the Company. Jeff George has nearly 20 years of global healthcare and corporate leadership experience. He is currently the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded, and an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm. Between 2008 and 2016, he served on the Executive Committee of Novartis Group AG, one of the largest global pharmaceutical companies, first as Division Head and CEO of Sandoz, Novartis’ $10 billion generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon, Novartis’ then $10 billion branded eye care subsidiary. In both roles, he was responsible for leading over 25,000 associates globally across more than 160 countries. More recently, he served as CEO and board member of Performance Health, the largest global manufacturer and distributor of products to the physical therapy and rehabilitation markets.

John Kiely

Mr. John J. Kiely CPA serves as Independent Director of the Company. Mr. Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. From 1980 to June 2019, he held various roles of increasing responsibility at Pricewaterhouse Coopers, including as U.S. Pharmaceutical Leader and Global Pharmaceutical Assurance Leader. Mr. Kiely is currently and has been since July 2019 on the board of directors of Zovio, Inc., an education technology services company. Mr. Kiely holds a bachelor of science degree from Saint Francis University.

Ted Nark

Mr. Ted Nark serves as Independent Director of the Company. Mr. Nark has served as Managing Director of KRG Capital Partners, a Denver-based $2 billion private equity fund, since 2007. In that role, Mr. Nark has led the identification, negotiation and due diligence of new acquisitions and has worked with portfolio companies and maintained relationships with limited partners. While at KRG, Mr. Nark has led the acquisition and successful monetization of companies including Convergint Technologies, Diversified Food Services and Petrochoice. From 2006 to 2007, Mr. Nark was a Partner at Leonard Green & Partners and from 2002 to 2006, he served as Chief Executive Officer and Chairman of the Board of White Cap Construction Supply, a Leonard Green-owned distributor of construction hardware, tools and materials to professional contractors in the United States. Previously, Mr. Nark served as Chief Executive Officer of Corporate Express Australia and Group President at Corporate Express Inc. Mr. Nark is currently a board member of several private companies such as Convergint Technologies, Western Windows, Trafficware, and The Maroon Group. Mr. Nark has previously served on the Boards of Corporate Express Australia, Fort Dearborn, White Cap Construction Supply, FTD, Leslies Pools, Gaiam, Real Goods Solar and Claim Jumper. Mr. Nark received a BS from Washington State University.

Shlomo Yanai

Mr. Shlomo Yanai serves as Independent Director of the Company. Mr. Yanai has more than 15 years of corporate leadership experience, primarily in the pharmaceutical industry. He served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Mr. Yanai currently serves as an advisor to CVC Capital Partners, a private equity firm. In addition, he currently serves on the boards of PDL BioPharma Inc. and WR Grace & Co. He previously served on the boards of Cambrex Corp., Lumenis Ltd., Perrigo Company and Sagent Pharmaceuticals, among others, and held various leadership positions in the Israel Defense Forces.

Basic Compensation